Regeneron Says Supreme Court Ruling Ends Patent Dispute With Amgen -- Update
19 May 2023 - 3:09AM
Dow Jones News
By Denny Jacob
Regeneron Pharmaceuticals on Thursday said a U.S. Supreme Court
opinion affirms a lower court opinion that held Amgen's asserted
U.S. PCSK9 patent claims were invalid.
Biotechnology company Regeneron said the Supreme Court's opinion
ends a nearly decade-long patent dispute related to its PCSK9
inhibitor, Praluent.
"We're gratified that the Supreme Court has affirmed the
position we have held for nearly ten years that Amgen's PCSK9
patents were overly broad and inconsistent with established case
law," said Executive Vice President Joseph LaRosa.
According to an Amgen spokeswoman, the company is disappointed
by the ruling, but "will continue to fight for patent laws and
policies that provide meaningful patent protection needed to foster
breakthrough innovation."
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 18, 2023 12:54 ET (16:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024